1-15 of 15
Suzanne A. Eccles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

Simon J. Anderhub, Grace Wing-Yan Mak, Mark D. Gurden, Amir Faisal, Konstantinos Drosopoulos, Katie Walsh, Hannah L. Woodward, Paolo Innocenti, Isaac M. Westwood, Sébastien Naud, Angela Hayes, Efthymia Theofani, Simone Filosto, Harry Saville, Rosemary Burke, Rob L.M. van Montfort, Florence I. Raynaud, Julian Blagg, Swen Hoelder, Suzanne A. Eccles, Spiros Linardopoulos
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (10): 1696–1707.
https://doi.org/10.1158/1535-7163.MCT-18-1203
Published: 01 October 2019
View article titled, High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Open the PDF for High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract A187: Exploring isoform-dependent functions of the mediator kinases in colorectal cancer

Olajumoke O. Popoola, Maria J. Ortiz-Ruiz, Konstantinos Mitsopoulos, Aurelie Mallinger, Robert Te-Poele, Kai Schiemann, Paul Workman, Dirk Wienke, Julian Blagg, Suzanne A. Eccles, Paul A. Clarke
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A187.
https://doi.org/10.1158/1535-7163.TARG-17-A187
Published: 01 January 2018
View article titled, Abstract A187: Exploring isoform-dependent functions of the mediator kinases in colorectal cancer
Journal Articles

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

Joo Ern Ang, Akos Pal, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de haven Brandon, Victoria L. Revell, Debra J. Skene, Miro Venturi, Ruediger Rueger, Valerie Meresse, Suzanne A. Eccles, Johann S. de Bono, Stanley B. Kaye, Paul Workman, Udai Banerji, Florence I. Raynaud
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (10): 2315–2323.
https://doi.org/10.1158/1535-7163.MCT-16-0881
Published: 02 October 2017
View article titled, Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma
Open the PDF for Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation

Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori Friedman, Mika Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (6): 1412–1424.
https://doi.org/10.1158/1535-7163.MCT-15-0815
Published: 02 June 2016
View article titled, Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Open the PDF for Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation in another window
Includes: Supplementary data
Journal Articles

Abstract PR02: Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology

Paul A. Clarke, Trevor Dale, Christina Esdar, Dennis Waalboer, Olajumoke Adeniji-Popoola, Maria-Jesus Ortiz-Ruiz, Aurelie Mallinger, Ken Ewan, Robert te Poele, Sharon Gowan, Paul Workman, Kai Schiemann, Suzanne A. Eccles, Dirk Wienke, Julian Blagg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PR02.
https://doi.org/10.1158/1535-7163.TARG-15-PR02
Published: 01 December 2015
View article titled, Abstract PR02: Identification of a potent and selective chemical probe for exploring the role of CDK8/19 in cancer biology
Journal Articles

Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

Thomas P. Matthews, Suki Klair, Kwai-Ming J. Cheung, Jane Scanlon, Michael Lainchbury, Nelly Piton, Martin Fisher, Michael Cherry, Kathy Boxall, Michael I. Walton, Isaac M. Westwood, Angela Hayes, Paul Eve, Melanie Valenti, Alexis de Haven Brandon, Gary Box, Rob L. M. van Montfort, David H. Williams, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Michelle D. Garrett, John C. Reader, Ian Collins
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A235.
https://doi.org/10.1158/1535-7163.TARG-11-A235
Published: 12 November 2011
View article titled, Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.
Journal Articles

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

Amir Faisal, Lynsey Vaughan, Vassilios Bavetsias, Chongbo Sun, Butrus Atrash, Sian Avery, Yann Jamin, Simon P. Robinson, Paul Workman, Julian Blagg, Florence I. Raynaud, Suzanne A. Eccles, Louis Chesler, Spiros Linardopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11): 2115–2123.
https://doi.org/10.1158/1535-7163.MCT-11-0333
Published: 08 November 2011
View article titled, The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes <em>MYCN</em>-Amplified Neuroblastoma <em>In Vivo</em>
Open the PDF for The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes <em>MYCN</em>-Amplified Neuroblastoma <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β

Aleksandra Bielen, Lara Perryman, Gary M. Box, Melanie Valenti, Alexis de Haven Brandon, Vanessa Martins, Alexa Jury, Sergey Popov, Sharon Gowan, Sebastien Jeay, Florence I. Raynaud, Francesco Hofmann, Darren Hargrave, Suzanne A. Eccles, Chris Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (8): 1407–1418.
https://doi.org/10.1158/1535-7163.MCT-11-0205
Published: 08 August 2011
View article titled, Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β
Open the PDF for Enhanced Efficacy of IGF1R Inhibition in Pediatric Glioblastoma by Combinatorial Targeting of PDGFRα/β in another window
Includes: Supplementary data
Journal Articles

Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930

Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan Henley, Lisa Pickard, Gowri Vijayaraghavan, John J. Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 360–371.
https://doi.org/10.1158/1535-7163.MCT-10-0760
Published: 08 February 2011
View article titled, Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Open the PDF for Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 in another window
Includes: Supplementary data
Journal Articles

Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma

Nathalie Gaspar, Swee Y. Sharp, Suzanne A. Eccles, Sharon Gowan, Sergey Popov, Chris Jones, Andrew Pearson, Gilles Vassal, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1219–1233.
https://doi.org/10.1158/1535-7163.MCT-09-0683
Published: 09 May 2010
View article titled, Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma
Open the PDF for Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma in another window
Includes: Supplementary data
Journal Articles

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon, Gary Box, Kathy J. Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, David H. Williams, John C. Reader, Ian Collins, Michelle D. Garrett
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 89–100.
https://doi.org/10.1158/1535-7163.MCT-09-0938
Published: 12 January 2010
View article titled, The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Open the PDF for The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106 in another window
Includes: Supplementary data
Journal Articles

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Florence I. Raynaud, Suzanne A. Eccles, Sonal Patel, Sonia Alix, Gary Box, Irina Chuckowree, Adrian Folkes, Sharon Gowan, Alexis De Haven Brandon, Francesca Di Stefano, Angela Hayes, Alan T. Henley, Letitia Lensun, Giles Pergl-Wilson, Anthony Robson, Nahid Saghir, Alexander Zhyvoloup, Edward McDonald, Peter Sheldrake, Stephen Shuttleworth, Melanie Valenti, Nan Chi Wan, Paul A. Clarke, Paul Workman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1725–1738.
https://doi.org/10.1158/1535-7163.MCT-08-1200
Published: 14 July 2009
View article titled, Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Open the PDF for Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 in another window
Includes: Supplementary data
Journal Articles

Changes in choline metabolism as potential biomarkers of phospholipase Cγ1 inhibition in human prostate cancer cells

Mounia Beloueche-Babari, Joanna C. Peak, L. Elizabeth Jackson, May-Yung Tiet, Martin O. Leach, Suzanne A. Eccles
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (5): 1305–1311.
https://doi.org/10.1158/1535-7163.MCT-09-0039
Published: 13 May 2009
View article titled, Changes in choline metabolism as potential biomarkers of phospholipase Cγ1 inhibition in human prostate cancer cells
Open the PDF for Changes in choline metabolism as potential biomarkers of phospholipase Cγ1 inhibition in human prostate cancer cells in another window
Journal Articles

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis

Sharon Sanderson, Melanie Valenti, Sharon Gowan, Lisa Patterson, Zahida Ahmad, Paul Workman, Suzanne A. Eccles
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (3): 522–532.
https://doi.org/10.1158/1535-7163.MCT-05-0439
Published: 16 March 2006
View article titled, Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis
Open the PDF for Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis in another window
Journal Articles

Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells

Mounia Beloueche-Babari, L. Elizabeth Jackson, Nada M.S. Al-Saffar, Suzanne A. Eccles, Florence I. Raynaud, Paul Workman, Martin O. Leach, Sabrina M. Ronen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (1): 187–196.
https://doi.org/10.1158/1535-7163.MCT-03-0220
Published: 23 January 2006
View article titled, Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Open the PDF for Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells in another window